Yes. Foreign patients can seek stem cell treatment in Japan, but a treating hospital or clinic must first review their records and accept the case. Visitors also need appropriate permission to enter and stay; Japan has a medical-stay visa scheme for foreign patients [1]. Acceptance, a visa, and payment do not establish that a proposed treatment is effective or approved for your condition.
A visa allows entry to Japan for care, while each hospital makes its own treatment decision. This article gives general information only and cannot clear any person for treatment.

Visitors and Foreign Residents
A visitor arranging a treatment trip needs to resolve entry requirements as well as medical acceptance. A foreign resident already living in Japan has a different administrative starting point. Neither status establishes eligibility for a particular cell treatment.
- Short-term visitor. MOFA runs a “Visa for Medical Stay” for treatment or check-ups at a Japanese medical institution, and the visa can include accompanying persons [1].
- Foreign resident. People who live in Japan and hold public insurance use different billing, but insurance does not automatically cover a cell therapy: many privately provided regenerative services remain self-pay, even for Japanese patients.
Two Legal Routes
For cell-based regenerative medicine offers, two regulatory distinctions matter: approval of a named product and provision of a service under Japan’s regenerative-medicine safety framework. Conventional blood stem cell transplantation for cancer is a separate clinical pathway discussed below.
| Route | What it is | What it does not mean |
|---|---|---|
| Approved regenerative medical product (under the PMD Act) | PMDA reviews a named product for quality, safety, and efficacy, and MHLW approves it for defined indications and uses. Each approval has its own review report [2] [3] | Approval of one product covers only its own indications. Japanese approval does not establish approval in another country; the United States maintains a separate list [4] |
| Private medical service or research (under the Act on the Safety of Regenerative Medicine) | The framework requires committee review and submission of a provision plan, with further requirements depending on the intervention and risk classification [5] [6] | A filed plan differs from product approval and provides no proof that the treatment works [2] |
Patients travelling to Japan should ask which route applies. For an approved product, the hospital should identify the product, current Japanese label, and indication; PMDA publishes individual review reports [3]. For a service under a provision plan, patients should request the institution and plan details rather than expecting a product approval report. This overview of Japan’s regenerative medicine registration and compliance explains the distinction.
What Approved Products Actually Cover
PMDA’s approval-history list covering April 2015 to July 2026 records products for specific indications. It does not list a general-purpose stem cell IV infusion approved for arthritis, fatigue, diabetes, or anti-aging [7]. A clinic’s offer for one of those purposes needs its own regulatory and evidence checks; the offer alone does not show that a valid provision plan exists. The examples below explain why a product name and diagnosis matter. Historical approval entries do not confirm present authorisation, supply, or acceptance of overseas patients.
Temcell for acute GVHD
Temcell contains donor bone marrow mesenchymal stem cells administered intravenously. Japan approved it in 2015 for acute graft-versus-host disease (GVHD), a complication after transplantation [7]. The supporting single-arm phase II/III trial included 25 patients with severe steroid-refractory acute GVHD. Twelve had a complete response lasting at least 28 days; the lower bound of the 95% confidence interval was below the historical 30% benchmark. Over the 52-week study, all 25 experienced adverse events, 22 had serious events, and 12 died. These events occurred in a severely ill population and the counts do not by themselves establish that Temcell caused them [8].
Stemirac for spinal cord injury
Stemirac contains the patient’s own bone marrow mesenchymal stem cells, given intravenously. It received conditional, time-limited approval in 2018 for traumatic spinal cord injury; that historical decision is not confirmation of its current approval or availability. The phase II open-label trial enrolled 17 people and treated 13. Twelve of the 13 improved by at least one American Spinal Injury Association Impairment Scale (AIS) grade at day 220 after injury. The trial had no control group, and all 13 treated patients experienced adverse events. Eligibility required initial enrolment within 14 days and treatment within 54 days after injury, so these results cannot establish benefit for an injury from years earlier [9].
JACC for cartilage defects
JACC is cultured cartilage made from the patient’s own cartilage cells, not a stem cell infusion. Japan first approved it in 2012 for specified traumatic knee cartilage defects and osteochondritis dissecans; a May 2025 indication extension included knee osteoarthritis with a cartilage defect of at least 2 cm² that does not respond to exercise or other conservative therapies. Surgeons implant the cultured cartilage during an operation. The review also describes selection requirements and long-term safety follow-up, so the defect size alone does not establish eligibility [10].
The small uncontrolled Temcell and Stemirac studies cannot establish a success rate for a future traveller or be compared as if they treated the same condition. Conditional and time-limited approval carries further evidence obligations; patients must verify the latest status rather than treating the original review as a current authorisation [2].
Medical Eligibility
For a foreign patient, the hospital’s decision rests on diagnosis, overall health, and the ability to complete treatment and follow-up, including travel home.
- Blood stem cell transplant. Doctors weigh the cancer type and stage, the patient’s own cells versus donor cells, donor availability, tolerance of intensive therapy, other illness, and prior treatment. NCI explains that donor-cell transplant patients may need to remain near the treating hospital and undergo prolonged follow-up; this is transplant care, not a timetable for a private regenerative-medicine infusion [11].
- Approved product. The specialist matches the patient’s diagnosis, stage, prior treatment, and procedure risks to the current product label.
- Private-clinic service. Patients should request the written protocol or filed plan details, consent documents, safety monitoring arrangements, and human data for the same condition [6].
Patients should tell the treating team about infection or fever, pregnancy or breastfeeding, organ disease, bleeding problems, cancer history, allergies, and all current medicines. This indications and contraindications guide lists questions to raise with the team. Patients should not stop prescribed medicines to try to qualify.
Medical Stay Visa
Travellers should confirm entry requirements with the Japanese embassy or consulate before making any payment [1]. A medical travel guide for stem cell treatment in Japan outlines the usual order of hospital confirmation, visa paperwork, and travel.
- Scope. Coverage includes treatment visits and check-ups, plus companions where needed, for acts a Japanese medical institution directs.
- Guarantor. Arrangements run through a registered guarantor, which coordinates the host institution and the certificate for planned services.
- Documents. Applicants submit a passport, application form, photo, hospital or guarantor certificate, bank-statement-level financial proof, and identity documents; exact requirements vary by nationality.
- Length of stay. Authorities grant 90 days, 6 months, or 1 year according to the medical condition. Stays over 90 days require hospitalisation plus a Certificate of Eligibility. Multiple-entry visas may extend to 3 years, with each visit limited to 90 days or less under a physician’s treatment plan.
- Companions. Family members and non-family companions may receive the same visa where care requires it. Companions may not engage in paid work in Japan.
For the medical-stay visa, MOFA directs patients to a registered guarantor, who helps arrange the host institution and obtain the certificate of planned services [1]. Patients also need written acceptance from the specific stem cell hospital in Japan. The MHLW foreign-patient list and JMIP accreditation are starting points only; neither confirms access to a particular cell treatment [12] [13].
Costs and Insurance
Travellers should budget for self-pay unless both the hospital and insurer confirm coverage for the exact procedure in writing. If there is no coverage, patients need a written self-pay quote and a plan for possible additional costs. MHLW recommends private medical insurance for visitors and warns about unpaid medical bills; travel insurance guidance does not confirm cover for an elective cell procedure [14].
- Itemised yen quote. Patients should obtain an itemised quote in yen covering the product name, cell source, dose, route, sessions, anaesthesia, admission, medicines, interpretation, follow-up, and the complication plan with costs. MHLW’s pricing manual only explains the calculation method; it is not a price list [15]. This cost overview explains the usual categories.
- Interpretation and records. Patients should confirm which interpretation the fee includes, who pays for translations, and whether scans from home need repeating.
- Aftercare. Before departure, patients should collect an English discharge summary, imaging records, a medication plan, and a named contact for complications.
Questions to Ask Before You Pay
Patients can use these six checks to organise the hospital’s written answers before committing to treatment.
| Question | A good answer | Warning sign |
|---|---|---|
| Which legal route is this? | A named approved product with its label, or a named filed plan with documents | Only “approved” or “registered,” with no product or plan details |
| What exactly is it approved or filed for? | A specific disease and patient group | “Many conditions” or “your whole body” |
| Will this hospital accept my case? | Written acceptance after reviewing your records | Pressure to pay before any medical review |
| What will it cost, and how long is the stay? | An itemised quote in yen and a schedule | One package price, or “a few days” for surgery and cell culture |
| What is the evidence for my condition? | A PMDA review report or peer-reviewed human data for the same product, route, and diagnosis | Testimonials only, or success rates with no diagnosis, dose, or follow-up |
| What happens after I go home? | A written follow-up and complication contact | No after-hours contact or discharge plan |
Claims of a cure, pressure to pay before medical review, and testimonials presented as evidence warrant caution. A research registration or a PubMed-indexed paper alone does not prove that an intervention works.
For example, if an offer says only “stem cells for knee pain,” a useful written reply would identify whether the proposal is an implanted cartilage product, a joint injection, or an IV infusion, then name the product or provision plan, the evidence for your diagnosis, and who will manage complications after you return home. This is a decision scenario, not a patient case or evidence of a treatment outcome.
Unsure which route fits your diagnosis?
Ask what information is needed to discuss an appointment. Your treating clinician must assess eligibility, explain the proposed treatment, and confirm its current regulatory status.
Ask about your caseThe Bottom Line
Foreign patients can seek treatment in Japan, but access depends on medical acceptance, the exact procedure, and appropriate entry arrangements. Before paying or travelling, patients should confirm the diagnosis, regulatory route, itemised yen quote, stay length, and aftercare. The hospital should verify the current Japanese label for an approved product or the applicable provision-plan documents for a service [1] [3] [6].
This article provides educational information rather than individual medical assessment. It confirms no treatment place, price, current supply, or clinical outcome.




